Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Direxion S&P Biotech Bull 3X (NY: LABU)
48.25 USD  +3.34 (+7.44%)
Official Closing Price  /  Updated: 7:59 PM EST, Nov 16, 2018  /  Add to My Watchlist      
View: Quote News
Fund Overview
Direxion S&P Biotech Bull 3X
Sector
Exchange Traded NY
Net Assets 208.03M
Inception Date
Related Funds
Quote
Price 48.25
Volume 4,724,300
Last Trade Nov 16, 7:59pm
Change (%)
+3.34 (7.44%)
Prev. Close 44.91
YTD %
-42.62%
Dividend Yield 0.24%
Performance
YTD
-35.84 (-42.62%)
1 Month
-15.74 (-24.60%)
3 Month
-39.13 (-44.78%)
6 Month
-38.54 (-44.41%)
1 Year
-20.24 (-29.55%)
Chart
Charting
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
LABU Crosses Critical Technical Indicator
In trading on Wednesday, shares of the Daily S&P Biotech Bull 3X Shares ETF (LABU) entered into oversold territory, changing hands as low as $40.58 per share. We define oversold territory using the... Read More
from ETF Channel
Biotech ETFs Hoping This Post-Election Trend Doesn’t Repeat
from ETF Trends
Top News
More News
After a Rough October, Leveraged Biotech ETF Looks to Bounce Back
from ETF Trends
How Democratic or Republican wins could divide tech stocks into winners and losers
A big Republican win could favor Apple, Alibaba and Nvidia. Read More
from MarketWatch
Gold Rally Pre-Market… Sustainable?
There is no significant news to reference as to why the US Dollar is falling. Read More
from Blogs - TalkMarkets
Daily S&P Biotech Bull 3X Shares Experiences Big Inflow
Symbols mentioned in this story: LABU Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded... Read More
from ETF Channel
XLC, LABU: Big ETF Inflows
Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the Communication Services Select Sector SPDR Fund (XLC), which added... Read More
from ETF Channel
Best & Worst Monthly Performers: September 26 Edition
Here is a look at the 25 best and 25 worst ETFs from the past trading month. Traders can use this list to find prospective candidates that have deviated too far from their longer-term trends, thereby... Read More
from ETFdb
Best & Worst Monthly Performers: September 26 Edition
Here is a look at the 25 best and 25 worst ETFs from the past trading month. Traders can use this list to find prospective candidates that have deviated too far from their longer-term trends, thereby... Read More
from ETFdb
Best August for US Stocks in 4 Years: 5 Top Leveraged ETFs
The month of August was strong for the U.S. stock market with the Dow Jones and the S&P 500 notching their best performances for the month since 2014, climbing 2.1% and 3%, respectively. Read More
from Blogs - TalkMarkets
Best & Worst Monthly Performers: August 29 Edition
Here is a look at the 25 best and 25 worst ETFs from the past month. Traders can use this list to find prospective candidates that have deviated too far from their longer-term trends, thereby serving... Read More
from ETFdb
Best & Worst Weekly Performers: July 28 Edition
Here is a look at the 25 best and 25 worst ETFs from the past week. Traders can use this list to find prospective candidates that have deviated too far from their longer-term trends, thereby serving as... Read More
from ETFdb
Exploring The Leveraged ETF Trade Heading Into Earnings Season
The second quarter earnings season is upon us, meaning traders and investors are primed to take advantage of volatile moves in ... Read More
from Benzinga
Best & Worst Weekly Performers: July 14 Edition
Here is a look at the 25 best and 25 worst ETFs from the past week. Traders can use this list to find prospective candidates that have deviated too far from their longer-term trends, thereby serving as... Read More
from ETFdb
Pharma, Biotech Bull ETFs Leading the Charge
The rising prices of drug treatments, more dependence on immuno-oncology and mergers focused on mid-sized biotech company acquisitions are just a few factors spurning the growth in the biotechnology... Read More
from ETF Trends
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.